Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Gross Margin · Q2 FY2027 · quarter ended Sep 2026

Gross margin narrows to 52.1%

Gross margin was 52.1% in Q2 FY2027, down 2.5 pp from a year earlier. On a trailing-twelve-month basis it was 49.5%, down 7.0 pp year over year. Over 3 fiscal years it narrowed by 3.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2026 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
52.1%+5.6 pp QoQ
Last fiscal yearMar 2026
52.8%-5.7 pp YoY
LTMSep 2026
49.5%-7.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.5 pp——
1 year-5.7 pp——
3 years-3.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2026
52.8%
Year-over-year change
-5.7pp

Gross Margin vs competitors

How RDY compares with its peers on the latest reported figures

  • RDY's LTM Sep 2026 gross margin of 49.5% is the 5th highest of the 8 companies compared; the peer median is 52.5%.
  • Its year-over-year change of -7.0 pp is the lowest of 7, against a peer median of +1.4 pp.
  • Over three fiscal years its change of -3.9 pp compares with a peer median of -0.3 pp.
RDY Competitors Peer median
Gross Margin for RDY and competitors
Company Period LTM level YoY 3-year change
BHCBausch Health Companies Inc.LTM Jun 202671.8% +1.1 pp-0.3 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202665.9% +6.6 pp-5.1 pp
HLNHaleon plcLTM Jun 202563.2% —+2.8 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202652.5% +2.9 pp+5.1 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202649.5% -7.0 pp-3.9 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202639.3% +1.7 pp+1.9 pp
VTRSViatris Inc.LTM Jun 202634.8% -1.8 pp-4.9 pp
Peer median (excluding RDY) 52.5%+1.4 pp-0.3 pp

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue214.39B245.88B279.16B325.54B353.47B
Cost of Revenue100.55B106.54B115.56B135.11B166.95B
Gross Profit113.84B139.34B163.61B190.43B186.52B
Gross Margin53.1%56.7%58.6%58.5%52.8%
Research & Development17.48B19.38B22.87B27.38B25.31B
Selling, General & Admin62.08B68.03B77.2B93.87B112.34B
Operating Expenses84.36B82.2B95.88B118.59B137.65B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
EBITDA45.08B74.43B88.42B96.67B83.29B
EBITDA Margin21.0%30.3%31.7%29.7%23.6%
Operating Income29.48B57.14B67.73B71.84B48.87B
Operating Margin13.7%23.2%24.3%22.1%13.8%
Interest Income965M1.18B2.28B2.68B8.28B
Interest Expense958M1.43B1.71B2.83B3.93B
Other Income / Expenses2.82B3.22B4.14B4.94B8.81B
Income Before Tax32.3B60.37B71.87B76.78B57.68B
Pre-Tax Margin15.1%24.6%25.7%23.6%16.3%
Income Tax Expense8.73B15.3B16.19B19.54B13B
Net Income23.57B45.07B55.68B56.54B45.09B
Net Margin11.0%18.3%19.9%17.4%12.8%
EPS (Basic)28.4254.2966.8067.8553.92
EPS (Diluted)28.3454.1766.8067.7753.92
Weighted Avg Shares829.41M830.17M833.54M833.31M832.41M
Weighted Avg Shares (Diluted)831.69M831.91M833.54M834.3M833.26M

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.